Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Application
Approval delays may affect long-term revenue projections, akin to other biotech cases.
Signal detail
Source-backed analysis, the reasoning behind the signal, and its market context.
Approval delays may affect long-term revenue projections, akin to other biotech cases.
What happened and why it matters
FDA issued a Complete Response Letter for APLT's govorestat NDA. Deficiencies in clinical application cited, delaying potential approval and launch. William Blair downgraded success probability for galactosemia to 30%. SORD program remains unaffected; potential revenue by late 2025 possible. APLT stock dropped 67.2% following the FDA's decision.
The CRL significantly impairs approval timeline, similar past reactions saw deeper declines.
FDA issued a Complete Response Letter for APLT's govorestat NDA.
Deficiencies in clinical application cited, delaying potential approval and launch.
William Blair downgraded success probability for galactosemia to 30%.
SORD program remains unaffected; potential revenue by late 2025 possible.
APLT stock dropped 67.2% following the FDA's decision.
Article outlines a critical setback which directly impacts APLT's viability and investor perception.
More AI-analyzed coverage connected to this story